A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver

LT Wang, LS Pereira, Y Flores-Garcia, J O'Connor… - Immunity, 2020 - cell.com
Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …

Mapping functional humoral correlates of protection against malaria challenge following RTS, S/AS01 vaccination

TJ Suscovich, JK Fallon, J Das, AR Demas… - Science translational …, 2020 - science.org
Vaccine development has the potential to be accelerated by coupling tools such as systems
immunology analyses and controlled human infection models to define the protective …

A candidate antibody drug for prevention of malaria

KL Williams, S Guerrero, Y Flores-Garcia, D Kim… - Nature medicine, 2024 - nature.com
Over 75% of malaria-attributable deaths occur in children under the age of 5 years.
However, the first malaria vaccine recommended by the World Health Organization (WHO) …

Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection

GM Martin, JL Torres, T Pholcharee, D Oyen… - Nature …, 2023 - nature.com
The generation of high-quality antibody responses to Plasmodium falciparum (Pf)
circumsporozoite protein (PfCSP), the primary surface antigen of Pf sporozoites, is …

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum

CTH Hayashi, Y Cao, LC Clark, AK Tripathi, F Zavala… - npj Vaccines, 2022 - nature.com
Malaria is a deadly disease responsible for between 550,000 and 627,000 deaths annually.
There is a pressing need to develop vaccines focused on malaria elimination. The complex …

A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum

N Beutler, T Pholcharee, D Oyen… - PLoS …, 2022 - journals.plos.org
Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS, S/AS01 is the first, and to date, the only vaccine that has …

[HTML][HTML] Cytotoxicity of human antibodies targeting the circumsporozoite protein is amplified by 3D substrate and correlates with protection

MC Aguirre-Botero, LT Wang, P Formaglio… - Cell reports, 2023 - cell.com
Human monoclonal antibodies (hmAbs) targeting the Plasmodium falciparum
circumsporozoite protein (PfCSP) on the sporozoite surface are a promising tool for …

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein

LT Wang, LS Pereira, PK Kiyuka, A Schön… - PLoS …, 2021 - journals.plos.org
Combinations of monoclonal antibodies (mAbs) against different epitopes on the same
antigen synergistically neutralize many viruses. However, there are limited studies …

The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo

Y Flores-Garcia, LT Wang, M Park, B Asady… - PLoS …, 2021 - journals.plos.org
Rare and potent monoclonal antibodies (mAbs) against the Plasmodium falciparum (Pf)
circumsporozoite protein (CSP) on infective sporozoites (SPZ) preferentially bind the PfCSP …

Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages

WC Huang, MT Mabrouk, L Zhou, M Baba… - Communications …, 2022 - nature.com
A vaccine targeting multiple stages of the Plasmodium falciparum parasite life cycle is
desirable. The sporozoite surface Circumsporozoite Protein (CSP) is the target of leading …